Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease

被引:2
|
作者
Saadati, Hassan [1 ]
Baradaran, Hamid Reza [1 ,2 ,3 ]
Danaei, Goodarz [4 ,5 ]
Ostovar, Afshin [6 ]
Hadaegh, Farzad [7 ]
Janani, Leila [8 ]
Steyerberg, Ewout W. [9 ,10 ]
Khalili, Davood [7 ,11 ]
机构
[1] Iran Univ Med Sci, Sch Publ Hlth, Dept Epidemiol, Tehran, Iran
[2] Med Sci & Nutr Univ Aberdeen, Inst Appl Hlth Sci, Sch Med, Ageing Clin & Expt Res Team, Aberdeen, Scotland
[3] Iran Univ Med Sci, Inst Endocrinol & Metab, Endocrine Res Ctr, Tehran, Iran
[4] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA
[5] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[6] Univ Tehran Med Sci, Osteoporosis Res Ctr, Endocrinol & Metab Clin Sci Inst, Tehran, Iran
[7] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Prevent Metab Disorders Res Ctr, Tehran, Iran
[8] Iran Univ Med Sci, Sch Publ Hlth, Dept Biostat, Tehran, Iran
[9] Leiden Univ, Dept Biomed Data Sci, Med Ctr, Leiden, Netherlands
[10] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands
[11] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Dept Biostat & Epidemiol, Tehran, Iran
关键词
Preferences; Statins; Benefit harm outcomes; Primary prevention; Cardiovascular disease; DISCRETE-CHOICE EXPERIMENTS; PATIENT PREFERENCES; AMERICAN-COLLEGE; RISK; PARTICIPANTS; METAANALYSIS;
D O I
10.1186/s12911-020-01304-w
中图分类号
R-058 [];
学科分类号
摘要
Background The use of statins for primary prevention of cardiovascular diseases is associated with different benefit and harm outcomes. The aime of this study is how important these outcomes are for people and what people's preferences are. Methods We conducted a preference-eliciting survey incorporating a best-worst scaling (BWS) instrument in Iran from June to November 2019. The relative importance of 13 statins-related outcomes was assessed on a sample of 1085 participants, including 913 general population (486 women) and 172 healthcare providers from the population covered by urban and rural primary health care centers. The participants made trade-off decisions and selected the most and least worrisome outcomes concurrently from 13 choice sets; each contains four outcomes generated using the balanced incomplete block design. Results According to the mean (SD) BWS scores, which can be (+ 4) in maximum and (- 4) in minimum, in the general population, the most worrisome outcomes were severe stroke (3.37 (0.8)), severe myocardial infarction (2.71(0.7)), and cancer (2.69 (1.33)). While myopathy (- 3. 03 (1.03)), nausea/headache (- 2.69 (0.94)), and treatment discontinuation due to side effects (- 2.24 (1.14)) were the least worrisome outcomes. Preferences were similar between rural and urban areas and among health care providers and the general population with overlapping uncertainty intervals. Conclusion The rank of health outcomes may be similar in various socio-cultural contexts. The preferences for benefits and harms of statin therapy are essential to assess benefit-harm balance when recommending statins for primary prevention of cardiovascular diseases.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease
    Hassan Saadati
    Hamid Reza Baradaran
    Goodarz Danaei
    Afshin Ostovar
    Farzad Hadaegh
    Leila Janani
    Ewout W. Steyerberg
    Davood Khalili
    BMC Medical Informatics and Decision Making, 20
  • [2] Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention
    Wang, Frances M.
    Yebyo, Henock G.
    Ballew, Shoshana H.
    Cainzos-Achirica, Miguel
    Boyd, Cynthia
    Puhan, Milo A.
    Matsushita, Kunihiro
    Blaha, Michael J.
    Schoenborn, Nancy L.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 13
  • [3] Statin Therapy for Primary Prevention of Cardiovascular Disease
    Taylor, Fiona C.
    Huffman, Mark
    Ebrahim, Shah
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (22): : 2451 - 2452
  • [4] Statin therapy for the primary prevention of cardiovascular disease: Pros
    Razavi, Alexander C.
    Mehta, Anurag
    Sperling, Laurence S.
    ATHEROSCLEROSIS, 2022, 356 : 41 - 45
  • [5] Statin therapy in primary and secondary cardiovascular disease prevention
    Paparodis, Rodis D.
    Bantouna, Dimitra
    Livadas, Sarantis
    Angelopoulos, Nicholas
    CURRENT ATHEROSCLEROSIS REPORTS, 2024, 27 (01)
  • [6] Statin therapy for the primary prevention of cardiovascular disease: Cons
    Durai, Vivek
    Redberg, Rita F.
    ATHEROSCLEROSIS, 2022, 356 : 46 - 49
  • [7] Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview
    Lippi, Giuseppe
    Danese, Elisa
    Favaloro, Emmanuel J.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2019, 45 (02): : 157 - 163
  • [8] BALANCING HARMS AND BENEFITS OF STATINS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A MICROSIMULATION MODELLING STUDY
    Chen, Tao
    Moeez, Subhani
    Soiland-Reyes, Claudia
    Simon, Capewell
    Martin, O'Flaherty
    Chris, Kypridemos
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2022, 76 : A20 - A20
  • [9] Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease
    Levy, DR
    Pearson, TA
    CLINICAL CARDIOLOGY, 2005, 28 (07) : 317 - 320
  • [10] Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients
    Timo E. Strandberg
    Current Atherosclerosis Reports, 2019, 21